|
1
|
Mayer RJ, Van Cutsem E, Falcone A, Yoshino
T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero
J, Komatsu Y, et al; RECOURSE Study Group, . Randomized trial of
TAS-102 for refractory metastatic colorectal cancer. N Engl J Med.
372:1909–1919. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Arnold M, Sierra MS, Laversanne M,
Soerjomataram I, Jemal A and Bray F: Global patterns and trends in
colorectal cancer incidence and mortality. Gut. 66:683–691. 2017.
View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Imperiale TF, Ransohoff DF, Itzkowitz SH,
Levin TR, Lavin P, Lidgard GP, Ahlquist DA and Berger BM:
Multitarget stool DNA testing for colorectal-cancer screening. N
Engl J Med. 370:1287–1297. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Bibbins-Domingo K, Grossman DC, Curry SJ,
Davidson KW, Epling JW Jr, García FAR, Gillman MW, Harper DM,
Kemper AR, Krist AH, et al; US Preventive Services Task Force, .
Screening for colorectal cancer: US Preventive Services Task Force
recommendation statement. JAMA. 315:2564–2575. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Koehler BC, Jassowicz A, Scherr AL, Lorenz
S, Radhakrishnan P, Kautz N, Elssner C, Weiss J, Jaeger D,
Schneider M, et al: Pan-Bcl-2 inhibitor Obatoclax is a potent late
stage autophagy inhibitor in colorectal cancer cells independent of
canonical autophagy signaling. BMC Cancer. 15:9192015. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Brown DG, Rao S, Weir TL, O'Malia J, Bazan
M, Brown RJ and Ryan EP: Metabolomics and metabolic pathway
networks from human colorectal cancers, adjacent mucosa, and stool.
Cancer Metab. 4:112016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Matsuda C, Munemoto Y, Mishima H, Nagata
N, Oshiro M, Kataoka M, Sakamoto J, Aoyama T, Morita S and Kono T:
Double-blind, placebo-controlled, randomized phase II study of
TJ-14 (Hangeshashinto) for infusional fluorinated-pyrimidine-based
colorectal cancer chemotherapy-induced oral mucositis. Cancer
Chemother Pharmacol. 76:97–103. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Gustavsson B, Carlsson G, Machover D,
Petrelli N, Roth A, Schmoll HJ, Tveit KM and Gibson F: A review of
the evolution of systemic chemotherapy in the management of
colorectal cancer. Clin Colorectal Cancer. 14:1–10. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Loupakis F, Cremolini C, Masi G, Lonardi
S, Zagonel V, Salvatore L, Cortesi E, Tomasello G, Ronzoni M, Spadi
R, et al: Initial therapy with FOLFOXIRI and bevacizumab for
metastatic colorectal cancer. N Engl J Med. 371:1609–1618. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ji J, Weng Q, Zhang F, Xiong F, Jin Y, Hui
J, Song J, Gao J, Chen M, Li Q, et al: Non-small-cell lung cancer:
Feasibility of intratumoral radiofrequency hyperthermia-enhanced
herpes simplex virus thymidine kinase gene therapy. Radiology.
288:612–620. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Thomas RG, Moon MJ, Lee H, Sasikala AR,
Kim CS, Park IK and Jeong YY: Hyaluronic acid conjugated
superparamagnetic iron oxide nanoparticle for cancer diagnosis and
hyperthermia therapy. Carbohydr Polym. 131:439–446. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Beriwal S, Shukla G, Shinde A, Heron DE,
Kelley JL, Edwards RP, Sukumvanich P, Richards S, Olawaiye AB and
Krivak TC: Preoperative intensity modulated radiation therapy and
chemotherapy for locally advanced vulvar carcinoma: Analysis of
pattern of relapse. Int J Radiat Oncol Biol Phys. 85:1269–1274.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Bui QC, Lieber M, Withers HR, Corson K,
van Rijnsoever M and Elsaleh H: The efficacy of hyperbaric oxygen
therapy in the treatment of radiation-induced late side effects.
Int J Radiat Oncol Biol Phys. 60:871–878. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van de Wetering M, Francies HE, Francis
JM, Bounova G, Iorio F, Pronk A, van Houdt W, van Gorp J,
Taylor-Weiner A, Kester L, et al: Prospective derivation of a
living organoid biobank of colorectal cancer patients. Cell.
161:933–945. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Heinemann V, von Weikersthal LF, Decker T,
Kiani A, Vehling-Kaiser U, Al-Batran SE, Heintges T, Lerchenmüller
C, Kahl C, Seipelt G, et al: FOLFIRI plus cetuximab versus FOLFIRI
plus bevacizumab as first-line treatment for patients with
metastatic colorectal cancer (FIRE-3): A randomised, open-label,
phase 3 trial. Lancet Oncol. 15:1065–1075. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
García-Carbonero R, van Cutsem E, Rivera
F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg
ZA, Funke R, et al: Randomized phase II trial of parsatuzumab
(anti-EGFL7) or placebo in combination with FOLFOX and bevacizumab
for first-line metastatic colorectal cancer. Oncologist.
22:375–e30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rahman MA, Matsumura Y, Yano S and Ochiai
B: pH-responsive charge-conversional and hemolytic activities of
magnetic nanocomposite particles for cell-targeted hyperthermia.
ACS Omega. 3:961–972. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Quinto CA, Mohindra P, Tong S and Bao G:
Multifunctional superparamagnetic iron oxide nanoparticles for
combined chemotherapy and hyperthermia cancer treatment. Nanoscale.
7:12728–12736. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Wan Y, Wang X, Zheng N and Shi J: Clinical
research of selective bronchial artery infusion and chemotherapy of
lung cancer. Zhongguo Fei Ai Za Zhi. 6:378–380. 2003.(In Chinese).
PubMed/NCBI
|
|
20
|
Yao X, Niu X, Ma K, Huang P, Grothe J,
Kaskel S and Zhu Y: Graphene quantum dots-capped magnetic
mesoporous silica nanoparticles as a multifunctional platform for
controlled drug delivery, magnetic hyperthermia, and photothermal
therapy. Small. 13:16022252017. View Article : Google Scholar
|
|
21
|
Datta NR, Ordóñez SG, Gaipl US, Paulides
MM, Crezee H, Gellermann J, Marder D, Puric E and Bodis S: Local
hyperthermia combined with radiotherapy and-/or chemotherapy:
Recent advances and promises for the future. Cancer Treat Rev.
41:742–753. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Ma L, Ruan L, Liu H, Yang H and Feng Y:
ABCB1 C3435T polymorphism is associated with leukemia
susceptibility: Evidence from a meta-analysis. Onco Targets Ther.
8:1009–1015. 2015.PubMed/NCBI
|
|
23
|
Gao LZ, Gao EM, Bai YF, Su HL, Zhang F, Ge
MQ, Liu DL and Huang YK: Hyperthermic intraperitoneal chemotherapy
plus high-frequency diathermic therapy followed by intravenous
chemotherapy versus intravenous chemotherapy alone for
postoperative adjuvant treatment of gastrointestinal cancer: A
comparative research study. J BUON. 21:1510–1517. 2016.PubMed/NCBI
|
|
24
|
Narayan P, Crocker I, Elder E and Olson
JJ: Safety and efficacy of concurrent interstitial radiation and
hyperthermia in the treatment of progressive malignant brain
tumors. Oncol Rep. 11:97–103. 2004.PubMed/NCBI
|
|
25
|
Chi MS, Yang KL, Chang YC, Ko HL, Lin YH,
Huang SC, Huang YY, Liao KW, Kondo M and Chi KH: Comparing the
effectiveness of combined external beam radiation and hyperthermia
versus external beam radiation alone in treating patients with
painful bony metastases: A phase 3 prospective, randomized,
controlled trial. Int J Radiat Oncol Biol Phys. 100:78–87. 2018.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Gani C, Schroeder C, Heinrich V, Spillner
P, Lamprecht U, Berger B and Zips D: Long-term local control and
survival after preoperative radiochemotherapy in combination with
deep regional hyperthermia in locally advanced rectal cancer. Int J
Hyperthermia. 32:187–192. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Chen K, Zhu S, Xiang G, Duan X, He J and
Chen G: Ablation effects of noninvasive radiofrequency
field-induced hyperthermia on liver cancer cells. Saudi Pharm J.
24:329–332. 2016. View Article : Google Scholar : PubMed/NCBI
|
